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Background: Weight loss is a common problem in patients with Squamous Cell Carcinoma of the Head and Neck
(SCCHN) treated with radiotherapy (RT). The aims of the present study were to determine if treated volume (TV), as
a measure of the radiation dose burden, can predict weight loss in patients with oropharyngeal cancer and to
analyze weight loss and body mass index (BMI) in the same patient group in relation to 5-year overall survival.
Methods: The ARTSCAN trial is a prospective, randomized, multicenter trial in patients with SCCHN. Nutritional data
from the ARTSCAN trial were analyzed retrospectively using univariate and multivariate statistical methods based on
information on percentage weight loss from the start of RT up to five months after the termination of RT (study
cohort 1, n = 232) and information on patients’ BMI at the start of RT (study cohort 2, n = 203). TV was defined as
the volume of the patient receiving at least 95% of the prescribed dose. TV64.6 Gy encompasses macroscopic tumor
and TV43.7 Gy elective lymph nodes of the neck.
Results: TV64.6 Gy and TV43.7 Gy were both significantly correlated with higher weight loss up to five months after
the termination of RT in study cohort 1 (p < 0.001 for both). BMI at the start of RT was shown to be a prognostic
factor for 5-year overall survival in study cohort 2 but weight loss was not. The hazard ratios and 95% confidence
intervals were 3.78 (1.46–9.75) and 2.57 (1.43–4.62) in patients with underweight and normal weight, respectively.
Conclusions: TV can predict weight loss during RT in patients with oropharyngeal cancer regardless of clinical
stage. A high BMI (>25 kg/m2) at the start of RT is positively associated with survival in patients with oropharyngeal
cancer.
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Weight loss is a common problem in patients with Squa-
mous Cell Carcinoma of the Head and Neck (SCCHN)
and this weight loss has a number of different etiologies
[1]. The tumor itself can affect nutritional status both by
its location and through metabolic alterations [2-5]. In
addition, the toxic effects of oncologic treatment such as
radiotherapy (RT) alone or in combination with surgery* Correspondence: sandra.ottosson@kost.umu.se
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unless otherwise stated.and/or anticancer drugs [6,7] can affect food intake [8-11]
and thus increase the risk of weight loss [8,9,11-13].
Weight loss is one of the main characteristics of mal-
nutrition [14]. However, not all patients with weight loss
will develop malnutrition. In clinical practice, weight loss
can be used together with body mass index (BMI) and
information about eating difficulties to find patients at risk
of nutritional deterioration [15]. It is recommended that
nutritional screening should be initiated before the start of
RT to find patients at risk and in need of nutritional inter-
ventions. Because the treatment for SCCHN can lead to
further nutritional impairment, predictive factors for antic-
ipated weight loss and nutritional decline during RT mightal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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during patient history. Research results available today
on patients with SCCHN suggest that tumor site, clinical
stage, and use of chemo-radiotherapy are factors that can
predict a significant weight loss during RT [16-18]. When
assessing the different tumor sites, patients with oro-
pharyngeal cancer have been shown to lose more weight
compared to patients with tumors at other sub-sites
[19-21]. In recent years, a number of publications have
addressed the dose-volume relationship in different or-
gans at risk (OARs) that affect swallowing function and
subsequently might lead to weight loss [22-25]. This
has also been shown for different tumor sub-sites, e.g.
oropharyngeal cancer [26-29].
The ARTSCAN trial is a Swedish multicenter, ran-
domized, controlled clinical trial in patients with SCCHN
comparing conventional fractionation (CF) with accele-
rated fractionation (AF) [30]. In previously published
results from the ARTSCAN trial, we found that pa-
tients with oropharyngeal cancer lost significantly
more weight during and after RT compared to patients
with tumors of the larynx and oral cavity [19]. In the
present study, we investigated the relationship between
the treated volume (TV) and weight loss in a
homogenous cohort at risk of weight loss who were
treated with RT. TV was used as a measure of the radi-
ation dose burden as defined by the International Com-
mission on Radiation Units & Measurements (ICRU,
reports 50 and 62) [31,32]. This study was performed
retrospectively using nutritional data from the sub-
group of patients with oropharyngeal cancer in the
ARTSCAN trial.
Earlier studies have investigated the relationship be-
tween different nutrition-related factors and survival in
patients with SCCHN [18,33-42]. The results tend to
vary, but the trend in the data suggests that BMI might
have a more prominent role in survival than weight
loss per se. Both McRackan et al. [40] and Pai et al.
[33] showed, for example, that patients with SCCHN
who had an initial BMI over 25 kg/m2 had a higher
chance of survival. The research available for weight
loss suggests that weight loss prior to treatment [35-37] or
weight loss in patients with recurrent disease [38,39]
might have a negative influence on survival. Given the
current research, the relation between BMI and sur-
vival needs to be further established in different sub-
groups of SCCHN. In addition, the correlation between
survival and weight loss during RT needs more thorough
investigation. In the present study, this is explored in the
same cohort of patients with oropharyngeal cancer as
described above.
Objectives
The aims of the present study were to: Analyze if TV can predict weight loss in patients
with oropharyngeal cancer and thereby provide
information on patients at risk of malnutrition and
in need of special nutritional surveillance.
 Analyze weight loss and BMI in patients with




This nutritional study is based on data from the ARTS-
CAN trial conducted between the years 1998 and 2006.
Seven hundred and fifty patients (age >18 years) with
non-distant metastatic SCCHN, i.e. cancer in the oral
cavity, oropharynx, hypopharynx, or larynx, were in-
cluded in the ARTSCAN trial at 12 treatment centers
across Sweden. Patients specifically with oropharyngeal
cancer were selected for the present study (n = 357). All
patients gave written consent before randomization,
and the study was approved by the local ethics commit-
tees (Dnr 07-023 M/FEK98-139). For more information
about the ARTSCAN trial, see Zackrisson et al. [30].
Data
Medical, treatment, and follow-up data were collected
prospectively in the ARTSCAN trial up to 5 years after
the termination of RT in surviving patients. After 5 years,
survival was followed through the Swedish population
registry. Details about the patient material, methods, and
structure for data collection in the ARTSCAN trial are
described elsewhere [30,43].
Radiotherapy
All patients received CT-based three-dimensional con-
formal radiotherapy (3-DCRT) and/or intensity-modulated
radiotherapy (IMRT) with dose prescriptions according
to the recommendations of the ICRU [31,32]. A more
detailed presentation of the RT and the quality assur-
ance process of the trial have been reported earlier
[30,43]. In short, 68 Gy was prescribed to the known
tumor in the oropharynx and metastatic cervical lymph
node/nodes. An additional adjuvant dose of 46 Gy was
prescribed to elective lymph nodes of the neck.
Absorbed doses and volumes TV, as a measure of the
radiation dose burden, was defined as the volume (cm3)
of the patient receiving at least 95% of the prescribed
dose [31,32]. TV64.6 Gy encompasses macroscopic tumor
and TV43.7 Gy elective lymph nodes of the neck.
Nutritional data
Weight was measured every week during RT, at 4-6
weeks after RT, every 3 months for the first 2 years after
RT, and thereafter every 6 months up to 5 years. In the
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after the termination of RT was calculated using weight at
the start of RT as the reference point. This time-period for
weight loss was chosen on the basis of previously pub-
lished results from the ARTSCAN trial showing a nadir of
weight loss for the entire cohort at 5 months after the ter-
mination of RT [19]. Weight loss was used either as a con-
tinuous variable or was dichotomized (<10% and ≥10%).
Patients with ≥10% weight loss were defined as at risk of
nutritional deterioration [44].
Height was gathered through the medical records and
used to calculate BMI (kg/m2). The following cut-off
values were used in the analyses: underweight BMI <
20 kg/m2 (or BMI < 22 kg/m2 if ≥70 years of age), normal
weight BMI 20–25 kg/m2 (or BMI 22–27 kg/m2 if ≥70 years
of age), and overweight/obesity BMI >25 kg/m2 (or
BMI >27 kg/m2 if ≥70 years of age) [15,45].
The patients could be classified into the following
three groups according to type of nutritional support ad-
ministered during the study: oral intake (with or without
nutritional counseling and/or oral nutritional supple-
ments), tube feeding (TF) using nasogastric feeding tube
or percutaneous endogastric gastrostomy, and parenteral
nutrition. The nutritional support was administered
when needed according to local guidelines at each par-
ticipating center. Use of TF and parenteral nutrition was
registered in the study protocol, and information on the
use of TF at the start and end of RT was used in the
present study.
Statistical analysis
The Statistical Package for the Social Sciences (SPSS)
version 21.0 and R version 2.15.2 software packages were
used for the statistical analyses. All tests were two-sided
and a p-value less than 0.05 was considered significant.
The independent samples t-test, one-way between-
groups ANOVA, and Fisher’s exact test were used for
univariate analyses. A multiple linear regression analysis
was used as the multivariate alternative, and variables
that were statistically significant in the univariate ana-
lyses were included as the independent variables in the
model. The dependent variable (weight change) was
numerical and the independent variables were either
numerical or dichotomized. The unstandardized regres-
sion coefficients (B) represent an increase (positive values)
or a decrease (negative values) in weight (percentage
points). A regression model based on cubic splines was
used to illustrate the nonlinear correlation between
weight loss and TV [46].
For the survival analyses, time to death was calculated
from the start of RT up to 5 years in surviving patients.
The Kaplan–Meier estimators for the BMI and weight
groups were compared using the log rank test. The Cox
proportional hazard model was used to calculate the hazardratios (HRs) and their 95% confidence intervals (CI). The
variable of interest (BMI) was included in the adjusted
model together with potential confounder variables related
to patient, tumour, and treatment characteristics. Variables
that did not meet the assumption of proportional hazard
were used as strata in the model.
Results
Eligibility and patient characteristics
Three hundred and fifty-seven patients were diagnosed
with oropharyngeal cancer in the ARTSCAN trial. A per
protocol analysis was performed, and percent weight
change between the start of RT up to 5 months after the
termination of RT was available for 232 patients (65.0%),
and these patients were referred to as study cohort 1.
The patients not included in this cohort were due to
death (n = 23), loss of follow-up or residual or recurrent
disease (n = 30), or missing data (n = 72). BMI at the
start of RT was available for 203 patients (56.9%) and
this group was named study cohort 2. Patient, tumor,
and treatment characteristics for all patients with oro-
pharyngeal cancer and for patients in study cohorts 1
and 2 are presented in Table 1.
Predictive factors for weight loss
Weight change from the start of RT up to 5 months
after the termination of RT in study cohort 1 (n = 232)
was analyzed together with tumor- and treatment-
related factors in univariate analyses (Table 2). The three
factors significantly related to weight loss were the use
of TF at the start of RT (p = 0.024), TV64.6 Gy (p < 0.001),
and TV43.7 Gy (p < 0.001).
Information about TF use at the start of RT was avail-
able for 230 patients (missing n = 2). Twelve patients
(5.2%) received TF at the start of RT. Information about
TV was available for 230 patients (missing n = 2). The
average volumes for TV64.6 Gy and TV43.7 Gy were
580 cm3 ± 265 cm3 and 1475 cm3 ± 592 cm3, respectively.
A multiple linear regression model was used to analyze
how much of the variation in weight loss that could be ex-
plained by the variables statistically significant in the uni-
variate analyses as well as the relation between the
dependent variable (weight loss up to 5 months after the
termination of RT) and each of the independent variables.
Because of the close relation between TV64.6 Gy and
TV43.7 Gy, two different analyses were performed. In the
first analysis, TF at the start of RT (yes/no) and TV64.6 Gy
(numerical) were included in the model (n = 228). Clinical
stage (I + II or III + IV) was also included as a confounding
factor for TV. The coefficient of determination (R2) was
0.084 (p < 0.001). The use of TF at the start of RT and
TV64.6 Gy were shown to be significantly predictive for
weight loss up to 5 months. Patients without TF at the
start of RT lost more weight than patients with TF (B =
Table 1 Characteristics of patients with oropharyngeal
cancer (n = 357) from the ARTSCAN trial as well as for











58 (32, 86) 57 (32, 86) 57 (32, 86)
<65 years 275 (77.0) 184 (79.3) 160 (78.8)
≥65 years 82 (23.0) 48 (20.7) 43 (21.2)
Sex
Male 267 (74.8) 173 (74.6) 154 (75.9)
Female 90 (25.2) 59 (25.4) 49 (24.1)
Clinical stage
I 10 (2.8) 8 (3.4) 9 (4.4)
II 20 (5.6) 16 (6.9) 13 (6.4)
III 84 (23.5) 54 (23.3) 41 (20.2)
IV 243 (68.1) 154 (66.4) 140 (69.0)
Surgery
Yes 166 (46.5) 103 (44.4) 106 (52.2)
No 191 (53.5) 129 (55.6) 97 (47.8)
Conventional
fractionation
178 (49.9) 117 (50.4) 106 (52.2)
Accelerated
fractionation
179 (50.1) 115 (49.6) 97 (47.8)
Number of
patients
n = 357 n = 232 n = 203
Table 2 Predictive factors for weight loss at 5 months after th
to weight at the start of RT (n = 232)
n
Tumor-related factors Clinical stage I + II 24
III + IV 20




Tube feeding at the start of RT Yes 12
No 21
Tube feeding at the end of RT Yes 10
No 12
Treated volume (cm3), mean ± SD TV64.6Gy 4
Treated volume (cm3), mean ± SD TV43.7Gy 12
*A p-value less than 0.05 was considered significant as determined by the independ
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had a significantly greater weight loss up to 5 months after
RT (B = −0.008, p < 0.001). The same multiple linear re-
gression analysis was performed with TV43.7 Gy (n = 228).
R2 was 0.142 (p < 0.001), and the presence of TF at the
start of RT and TV43.7 Gy were shown to be significantly
predictive for weight loss up to 5 months. Patients without
TF at the start of RT lost more weight than patients with
TF (B = 5.250, p = 0.017), and patients treated with larger
TV43.7 Gy had a significantly larger weight loss up to
5 months after RT (B = −0.005, p < 0.001). Clinical stage
was not significantly predictive for weight loss in either
of the multivariate models (p = 0.449 and p = 0.138,
respectively).
A regression model based on cubic splines was used to il-
lustrate the nonlinear relationship between weight change
up to 5 months after RT and TV64.6 Gy (Figure 1) and
TV43.7 Gy (Figure 2) while also controlling for clinical stage
and TF at the start of RT (n = 228). For TV43.7 Gy (Figure 2),
the relation between weight and TV displayed an almost
linear shape. However, another type of relation was found
between weight and TV64.6 Gy (Figure 1). Between
500 cm3 and 1000 cm3, the weight seemed to stabilize,
and for volumes above 1000 cm3 the volume effect on
weight loss increased more steeply. Above 1500 cm3,
the 95% CI became wider due to fewer events.
Weight and BMI in relation to 5-year overall survival
Percent weight change from the start of RT up to
5 months after the termination of RT was dichoto-
mized into <10% (n = 74) and ≥10% (n = 158) and ana-
lyzed in relation to 5-year overall survival in study
cohort 1 (n = 232). The 5-year overall survival rates fore termination of radiotherapy (RT) is shown in relation
(%) Weight loss % mean ± SD p-value* Missing data
(10.3) −12.96 ± 7.36 0.643 -
8 (89.7) −13.74 ± 7.95
7(50.4) −12.96 ± 7.86 0.170 -
5 (49.6) −14.38 ± 7.86
1 (43.5) −13.97 ± 7.82 0.601 -
1 (56.5) −13.42 ± 7.94
(5.2) −8.70 ± 8.16 0.024 2
8 (94.8) −13.97 ± 7.79
3 (46.0) −12.82 ± 8.56 0.126 8
1 (54.0) −14.45 ± 7.36
Weight loss%
<10% ≥10%
94.00 ± 190.43 621.00 ± 285.54 <0.001 2
47.66 ± 481.94 1583.26 ± 610.24 <0.001 2
ent samples t-test. †Conventional fractionation. ‡Accelerated fractionation.
Figure 1 Nonlinear correlation between treated volume
(TV64.6 Gy) and weight change. Regression model based on cubic
splines for weight change in percent (95% CI) from the start of RT
up to 5 months after RT with TV64.6 Gy and controlling for clinical
stage and tube feeding at the start of RT (n = 228).
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respectively (log rank: p = 0.708).
According to the three BMI classifications, 8.4% of the
patients were underweight, 33.0% were normal weight,
and 58.6% were overweight or obese at the start of RT. Pa-
tients with overweight or obesity had a significantly higher
percent weight loss up to 5 months (15.3%) compared toFigure 2 Nonlinear correlation between treated volume
(TV43.7 Gy) and weight change. Regression model based on cubic
splines for weight change in percent (95% CI) from the start of RT
up to 5 months after RT with TV43.7 Gy and controlling for clinical
stage and tube feeding at the start of RT (n = 228).patients with normal weight (11.8%, p = 0.022) or under-
weight (4.9%, p < 0.001).
BMI at the start of RT was analyzed in relation to 5-
year overall survival in study cohort 2 (n = 203). There
was a significant difference in 5-year overall survival be-
tween patients with different BMI at the start of RT (log
rank: p < 0.001) (Figure 3). Patients who were under-
weight and normal weight at the start of RT had lower
survival rates (58.8% and 56.7%, respectively) than pa-
tients who were overweight or obese (83.2%). For the
unadjusted Cox regression analysis, the HRs and 95% CI
were 3.31 (1.40–7.83) (p = 0.006) and 3.07 (1.74–5.44)
(p < 0.001) for patients with underweight or normal
weight, respectively. In the adjusted Cox regression, the
following variables were included together with BMI:
age (numerical value), sex (male/female), clinical stage
(I + II or III + IV, used as strata), RT schedule (CF/AF),
and surgery (yes/no). The HRs and 95% CI were 3.78
(1.46–9.75) (p = 0.006) and 2.57 (1.43–4.62) (p = 0.002) in
patients with underweight and normal weight, respectively.
Discussion
It is well known that RT for oropharyngeal cancer can
lead to nutritional deterioration. The present study has
retrospectively explored TV as a predictive factor forFigure 3 Overall survival by body mass index (BMI) category.
Kaplan–Meier plot of overall survival by BMI category at the start of
RT (n = 203). The following cut-off values were used in the analyses:
underweight BMI < 20 kg/m2 (or BMI < 22 kg/m2 if ≥70 years of age),
normal weight BMI 20–25 kg/m2 (or BMI 22–27 kg/m2 if ≥70 years of
age), and overweight/obesity BMI >25 kg/m2 (or BMI >27 kg/m2
if ≥70 years of age).
Ottosson et al. Radiation Oncology 2014, 9:160 Page 6 of 8
http://www.ro-journal.com/content/9/1/160weight loss as well as weight loss and BMI in relation to
5-year overall survival in a cohort consisting of patients
with oropharyngeal cancer under nutritional surveillance.
A major finding was that TV, as a measure of the radiation
dose burden, was of greater predictive value than clinical
stage for weight loss from the start of RT up to 5 months
after the termination of RT. Another finding was that pa-
tients with overweight or obesity had better 5-year overall
survival when compared to patients with underweight and
normal weight. The same relation could not be shown for
weight loss and 5-year overall survival.
A higher degree of treatment toxicity due to a larger
radiation dose burden might be a possible explanation as
to why patients in the present study who were treated
with larger TV had significantly greater weight loss. It is
obvious that the larger the TV the higher the risk for ex-
ceeding the dose volume constraints in a number of
OARs. Despite increasing knowledge on such parameters,
there is still a lack of detailed information for several
OARs concerning the interrelationship and risks from
combined dose-volume responses. For that reason, the TV
in a defined set of organs might be useful as a surrogate
parameter. This might be of particular use for weight loss,
which is highly multi-factorial. Dysphagia is known to be
related to the prescribed dose in specific OARs [22-25]
and in addition, other side effects of RT such as mucositis
and xerostomia [1,6] are known to be related to the irradi-
ated volume. The size of the TV alone might thus predict
weight loss, regardless of included OARs, through both
locally (increased toxicity response) and systemic effects
[47]. It can be speculated that inflammatory mediators
produced in response to RT could have a negative influ-
ence on the physiological regulation of the appetite thus
leading to decreased food intake [2]. Hence, the data
from this site-specific cohort support the notion that
TV can be used during RT planning to predict which
patients are at risk of weight loss and, therefore, are in
need of special nutritional surveillance during RT.
The finding that larger TV can predict patients at risk
for increased weight loss during and after RT prompted
us to further investigate whether there was a specific cut-
off for the analyzed TVs that could be used in a clinical
setting. For TV64.6 Gy, the volume effect on weight loss
increased for volumes above 1000 cm3. However, as the
95% CI became wider above 1500 cm3 and therefore
more difficult to interpret, more studies are needed in
order to identify if there exists any specific volume cut-
off with clinical relevance.
The results from the current study cannot confirm that
weight loss per se is a negative prognostic factor in pa-
tients with oropharyngeal cancer. In fact, patients with a
high BMI showed the largest weight loss but still had a
better 5-year overall survival. This indicates that pretreat-
ment BMI can be used as a prognostic indicator for 5-yearoverall survival in patients with oropharyngeal cancer but
weight loss in connection to treatment cannot. However,
it is difficult to come to any conclusion regarding ob-
jective nutritional measures as prognostic indicators for
survival in SCCHN because of the diverse nature of the
available literature in terms of both results and study
design [18,33-42]. Still, the results from the present
study for BMI confirm the results of previous research
[33,40,41]. The relation between a higher BMI and greater
survival might be explained by the larger amount of adi-
pose tissue available to overweight and obese patients. It
seems as though the amount of fat mass might deter-
mine the amount of lean body mass that can be spared
during negative energy balance [48], and this might be
of significant clinical value.
Interpretation of the results in this study showing a
significant relationship between BMI and survival in pa-
tients with oropharyngeal cancer must take confounding
factors into consideration. Previous well-known prog-
nostic factors for survival in oropharyngeal cancer are
stage, human papilloma virus (HPV) infection, and
smoking [49,50]. Prevalence of HPV infection and smok-
ing habits could not be controlled for in the present
study because this information was not available for the
study cohort. However, when controlling for smoking in
a multivariate analysis, McRackan et al. [40] still found a
significant impact of BMI on survival. Because the ma-
jority of patients with oropharyngeal cancer are cur-
rently HPV-positive, it is less probable that HPV is a
confounder for BMI. However, the relation between
HPV and BMI needs to be better assessed.
One limitation of this study is the number of patients
available for analysis. The information on BMI and weight
was reduced primarily due to missing data, which implies
a potential selection bias of patients available for analysis.
In addition, few patients received TF at the start of RT
and this should be considered when interpreting the re-
sult from the regression analysis. However, one of the
strengths of the current study was that all participants
had oropharyngeal cancer making the cohort homogenous.
The present study has important clinical implications.
TV, defined as the volume of the body encompassed by
the 95% isodose of the prescribed dose [31,32], was reg-
istered in the ARTSCAN database and was thus chosen
in this study as a measure of the radiation dose burden
to the patient. The TV might not always be available for
the pretreatment decision of a nutritional intervention.
With highly conformal RT, the result for the TV might
well be transferred to the delineated target, i.e. the plan-
ning target volume (PTV). For example, Mallick and co-
workers [20] studied PTV instead of TV in relation to
weight loss during RT and found a significant impact of
larger PTV on weight loss. In this study, the conformity
index [32] of TV64.6 Gy/PTV68 Gy was 1.89 ± 0.59 and the
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This suggests that both the PTV and TV can be used as
predictors for weight loss and highlights the importance
of concise target delineation. Also, based on the results of
the present study it seems desirable to strive for a high
BMI before initiating RT. In addition, future prospective
studies should investigate whether nutritional interven-
tions can improve outcomes in patients with less benefi-
cial nutritional status at the start of RT.
Conclusions
The results of the present study showed that larger
TV64.6 Gy and TV43.7 Gy were associated with increased
weight loss up to 5 months after the termination of RT
regardless of clinical stage. Therefore, TV can be used to
identify patients at risk of malnutrition and in need of
special nutritional surveillance during RT. The results
also showed that BMI at the start of RT can be used as a
prognostic factor for 5-year overall survival.
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